The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|March 13, 2017
Special Clinical Research Summit on Brexit Set for April
Author(s)Philip Ward
An emergency summit to discuss how to safeguard the clinical research industry in the U.K. before and after Brexit will take place on April 5.
Advertisement
An emergency summit to discuss how to safeguard the clinical research industry in the U.K. before and after Brexit-the planned exit of the U.K. from the European Union (EU)-will take place on Wednesday, April 5th at a venue in the South Bucks/Berkshire area.
“Pressure is mounting on the government because the issue is very real. The clinical research industry is already experiencing a challenging time with the ongoing talent crisis. It’s important we proactively manage the transition through Brexit to avoid long-term issues to the industry,” says Jacqueline Johnson North, CEO of IAOCR, the accrediting organization for the international clinical research industry. “We can’t wait for the Government to make decisions. By working together, we will have a stronger voice in Parliament.”
The clinical research sector is of great value to the U.K. economy, and many CROs and pharmaceutical companies have established their European headquarters in the country, she continued. Globally there is also a talent crisis, which means the U.K. needs to attract and retain talent, both now and in the future, and the implications of Brexit must be considered and proactively managed.
Clinical research staff and the companies employing them are operating in times of uncertainty, according to Johnson North. The current position of the U.K. government is that it is unwilling to guarantee the rights of EU nationals from other countries to remain in the country, until the rights of U.K. nationals living in the EU have been secured.
The initial meeting will focus on protecting the current and future talent of the industry, as well as defining other key issues that the industry needs to consider as the UK prepares to exit the EU. It will create a taskforce to develop a practical, strategic positioning paper with clear messages on what the clinical research industry needs to survive and thrive pre- and post-Brexit.
“We have had a lot of interest in the summit and we will be reviewing all interested parties next week,” noted Jane Gulmez, Global Client Communications Manager of IAOCR.
For more details about the event, contact her on +44 (0) 1628 565 544 or by email at jgulmez@iaocr.com.
Philip Ward is the European Editor for Applied Clinical Trials
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5